Neurones (NRO) - Net Assets
Based on the latest financial reports, Neurones (NRO) has net assets worth €464.87 Million EUR (≈ $543.48 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€749.03 Million ≈ $875.70 Million USD) and total liabilities (€284.16 Million ≈ $332.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Neurones tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €464.87 Million |
| % of Total Assets | 62.06% |
| Annual Growth Rate | 10.03% |
| 5-Year Change | 31.72% |
| 10-Year Change | 94.95% |
| Growth Volatility | 3.2 |
Neurones - Net Assets Trend (2000–2025)
This chart illustrates how Neurones's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Neurones to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Neurones (2000–2025)
The table below shows the annual net assets of Neurones from 2000 to 2025. For live valuation and market cap data, see Neurones (NRO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €464.87 Million ≈ $543.48 Million |
+6.58% |
| 2024-12-31 | €436.17 Million ≈ $509.93 Million |
+6.93% |
| 2023-12-31 | €407.91 Million ≈ $476.89 Million |
+8.61% |
| 2022-12-31 | €375.58 Million ≈ $439.09 Million |
+6.42% |
| 2021-12-31 | €352.92 Million ≈ $412.60 Million |
-1.70% |
| 2020-12-31 | €359.02 Million ≈ $419.74 Million |
+9.69% |
| 2019-12-31 | €327.32 Million ≈ $382.67 Million |
+10.63% |
| 2018-12-31 | €295.88 Million ≈ $345.91 Million |
+10.38% |
| 2017-12-31 | €268.05 Million ≈ $313.38 Million |
+12.41% |
| 2016-12-31 | €238.46 Million ≈ $278.78 Million |
+10.52% |
| 2015-12-31 | €215.75 Million ≈ $252.23 Million |
+9.59% |
| 2014-12-31 | €196.88 Million ≈ $230.17 Million |
+12.37% |
| 2013-12-31 | €175.21 Million ≈ $204.84 Million |
+12.73% |
| 2012-12-31 | €155.42 Million ≈ $181.70 Million |
+11.71% |
| 2011-12-31 | €139.13 Million ≈ $162.65 Million |
+14.67% |
| 2010-12-31 | €121.33 Million ≈ $141.84 Million |
+12.05% |
| 2009-12-31 | €108.28 Million ≈ $126.59 Million |
+11.73% |
| 2008-12-31 | €96.91 Million ≈ $113.30 Million |
+12.83% |
| 2007-12-31 | €85.89 Million ≈ $100.41 Million |
+12.26% |
| 2006-12-31 | €76.51 Million ≈ $89.45 Million |
+8.30% |
| 2005-12-31 | €70.65 Million ≈ $82.60 Million |
+9.20% |
| 2004-12-31 | €64.70 Million ≈ $75.64 Million |
+9.74% |
| 2003-12-31 | €58.96 Million ≈ $68.93 Million |
+8.96% |
| 2002-12-31 | €54.11 Million ≈ $63.26 Million |
+12.81% |
| 2001-12-31 | €47.97 Million ≈ $56.08 Million |
+12.52% |
| 2000-12-31 | €42.63 Million ≈ $49.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neurones's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 37136900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €371.37 Million | 92.85% |
| Common Stock | €9.73 Million | 2.43% |
| Other Comprehensive Income | €3.75 Million | 0.94% |
| Other Components | €15.13 Million | 3.78% |
| Total Equity | €399.98 Million | 100.00% |
Neurones Competitors by Market Cap
The table below lists competitors of Neurones ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sharda Cropchem Limited
NSE:SHARDACROP
|
$886.18 Million |
|
Standard Lithium Ltd
NYSE MKT:SLI
|
$886.39 Million |
|
Appian Corp
NASDAQ:APPN
|
$886.70 Million |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
$886.72 Million |
|
Vertex
NASDAQ:VERX
|
$885.83 Million |
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
$885.49 Million |
|
CureVac NV
F:5CV
|
$885.32 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
$885.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurones's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 378,104,000 to 399,980,000, a change of 21,876,000 (5.8%).
- Net income of 61,900,000 contributed positively to equity growth.
- Dividend payments of 31,624,000 reduced retained earnings.
- Share repurchases of 316,000 reduced equity.
- Other comprehensive income decreased equity by 296,012,000.
- Other factors increased equity by 287,928,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €61.90 Million | +15.48% |
| Dividends Paid | €31.62 Million | -7.91% |
| Share Repurchases | €316.00K | -0.08% |
| Other Comprehensive Income | €-296.01 Million | -74.01% |
| Other Changes | €287.93 Million | +71.99% |
| Total Change | €- | 5.79% |
Book Value vs Market Value Analysis
This analysis compares Neurones's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.56x to 2.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €2.20 | €34.30 | x |
| 2003-12-31 | €2.34 | €34.30 | x |
| 2004-12-31 | €2.62 | €34.30 | x |
| 2005-12-31 | €2.89 | €34.30 | x |
| 2006-12-31 | €2.97 | €34.30 | x |
| 2007-12-31 | €3.41 | €34.30 | x |
| 2008-12-31 | €3.83 | €34.30 | x |
| 2009-12-31 | €4.35 | €34.30 | x |
| 2010-12-31 | €4.82 | €34.30 | x |
| 2011-12-31 | €5.39 | €34.30 | x |
| 2012-12-31 | €6.00 | €34.30 | x |
| 2013-12-31 | €6.73 | €34.30 | x |
| 2014-12-31 | €7.45 | €34.30 | x |
| 2015-12-31 | €8.22 | €34.30 | x |
| 2016-12-31 | €8.95 | €34.30 | x |
| 2017-12-31 | €10.00 | €34.30 | x |
| 2018-12-31 | €10.99 | €34.30 | x |
| 2019-12-31 | €12.23 | €34.30 | x |
| 2020-12-31 | €13.29 | €34.30 | x |
| 2021-12-31 | €12.85 | €34.30 | x |
| 2022-12-31 | €13.61 | €34.30 | x |
| 2023-12-31 | €14.58 | €34.30 | x |
| 2024-12-31 | €15.53 | €34.30 | x |
| 2025-12-31 | €13.84 | €34.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurones utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.48%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.22%
- • Asset Turnover: 1.14x
- • Equity Multiplier: 1.87x
- Recent ROE (15.48%) is above the historical average (11.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 9.14% | 5.82% | 1.06x | 1.48x | €-361.10K |
| 2001 | 11.08% | 6.10% | 1.15x | 1.58x | €509.30K |
| 2002 | 11.53% | 6.43% | 1.17x | 1.53x | €790.80K |
| 2003 | 8.70% | 5.24% | 1.13x | 1.47x | €-725.60K |
| 2004 | 8.62% | 5.59% | 1.04x | 1.48x | €-871.50K |
| 2005 | 8.64% | 5.44% | 1.08x | 1.47x | €-935.30K |
| 2006 | 9.22% | 5.08% | 1.10x | 1.65x | €-560.90K |
| 2007 | 12.04% | 6.38% | 1.15x | 1.64x | €1.68 Million |
| 2008 | 14.21% | 6.85% | 1.14x | 1.81x | €3.85 Million |
| 2009 | 12.57% | 5.92% | 1.28x | 1.66x | €2.62 Million |
| 2010 | 13.08% | 6.24% | 1.26x | 1.66x | €3.52 Million |
| 2011 | 11.44% | 5.22% | 1.26x | 1.74x | €1.86 Million |
| 2012 | 10.30% | 4.71% | 1.26x | 1.73x | €427.00K |
| 2013 | 11.48% | 5.41% | 1.23x | 1.72x | €2.39 Million |
| 2014 | 11.36% | 5.77% | 1.17x | 1.69x | €2.45 Million |
| 2015 | 10.76% | 5.35% | 1.14x | 1.77x | €1.52 Million |
| 2016 | 11.61% | 5.64% | 1.16x | 1.78x | €3.50 Million |
| 2017 | 11.24% | 5.63% | 1.18x | 1.69x | €3.01 Million |
| 2018 | 9.73% | 5.30% | 1.09x | 1.68x | €-724.10K |
| 2019 | 10.36% | 6.04% | 1.00x | 1.72x | €1.08 Million |
| 2020 | 9.58% | 5.89% | 0.95x | 1.70x | €-1.34 Million |
| 2021 | 12.10% | 6.50% | 1.02x | 1.82x | €6.55 Million |
| 2022 | 13.38% | 6.65% | 1.08x | 1.86x | €11.18 Million |
| 2023 | 13.94% | 6.67% | 1.10x | 1.90x | €13.97 Million |
| 2024 | 13.89% | 6.48% | 1.12x | 1.92x | €14.69 Million |
| 2025 | 15.48% | 7.22% | 1.14x | 1.87x | €21.90 Million |
Industry Comparison
This section compares Neurones's net assets metrics with peer companies in the Information Technology Services industry.
Industry Context
- Industry: Information Technology Services
- Average net assets among peers: $557,255,111
- Average return on equity (ROE) among peers: 15.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurones (NRO) | €464.87 Million | 9.14% | 0.61x | $885.97 Million |
| Hitechpros (ALHIT) | $3.56 Million | 39.38% | 1.63x | $24.23 Million |
| IT Link (ALITL) | $4.94 Million | 15.53% | 2.80x | $29.34 Million |
| Keyrus SA (ALKEY) | $46.99 Million | -1.02% | 5.84x | $112.89 Million |
| Alten SA (ATE) | $2.22 Billion | 4.81% | 0.64x | $2.20 Billion |
| Atos SE (ATO) | $1.66 Billion | 2.15% | 1.61x | $786.13 Million |
| Aubay Société Anonyme (AUB) | $143.86 Million | 16.64% | 1.11x | $662.40 Million |
| Capgemini SE (CAP) | $1.36 Billion | 3.16% | 0.97x | $16.80 Billion |
| Union Technologies Informatique Group S.A (FPG) | $3.95 Million | -2.89% | 2.85x | $7.79 Million |
| Infotel SA (INF) | $117.88 Million | 15.33% | 1.17x | $256.81 Million |
| Cheops Technology France SA (MLCHE) | $1.78 Million | 62.36% | 1.98x | $126.50 Million |
About Neurones
Neurones S.A. provides infrastructure, application, and consulting services in France. The company offers cloud, infrastructure management, DevOps, cybersecurity, user support, IT service management, information system governance, and automation services. It also provides digital, UX/UI, agile, devOps, mobility, and data; SAP integration and outsourcing content management, business process manage… Read more